Research advances in add-on treatment for negative symptoms and cognitive dysfunction in schizophrenia.
10.11817/j.issn.1672-7347.2020.190556
- Author:
Ranran LI
1
;
Gangrui HEI
2
;
Ye YANG
2
;
Renrong WU
2
;
Jingping ZHAO
3
Author Information
1. Department of Psychiatry, Shandong Mental Health Center, Jinan 250014. dtlrr113@126.com.
2. Department of Psychiatry, Second Xiangya Hospital, Central South University, Changsha 410011, China.
3. Department of Psychiatry, Second Xiangya Hospital, Central South University, Changsha 410011, China. zhaojingping@csu.edu.cn.
- Publication Type:Journal Article
- Keywords:
add-on treatment;
cognitive dysfunction;
negative symptoms;
schizophrenia
- MeSH:
Anti-Inflammatory Agents/therapeutic use*;
Antipsychotic Agents/therapeutic use*;
Cognitive Dysfunction/etiology*;
Humans;
Minocycline/therapeutic use*;
Schizophrenia/drug therapy*
- From:
Journal of Central South University(Medical Sciences)
2020;45(12):1457-1463
- CountryChina
- Language:English
-
Abstract:
Antipsychotic medication is the primary treatment for schizophrenia, which is effective on ameliorating positive symptoms and can reduce the risk of recurrence, but it has limited efficacy for negative symptoms and cognitive dysfunction. The negative symptoms and cognitive dysfunction seriously affects the life quality and social function for the patients with schizophrenia. Currently, there is plenty evidence that antipsychotic drugs combined with adjuvant therapy drugs can effectively improve the negative symptoms and cognitive dysfunction. These drugs include anti-oxidants, nicotinic acetylcholine receptors and neuro-inflammatory drugs (anti-inflammatory drugs, minocycline), which show potential clinical effects.
